Bio Solution Co.,Ltd. Stock price

Equities

A086820

KR7086820008

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
18,370 KRW +0.38% Intraday chart for Bio Solution Co.,Ltd. +0.60% -5.26%
Sales 2019 8.88B 6.59M Sales 2020 7.74B 5.75M Capitalization 235B 174M
Net income 2019 -698M -518K Net income 2020 -1.8B -1.34M EV / Sales 2019 34 x
Net cash position 2019 39.72B 29.47M Net cash position 2020 34.77B 25.8M EV / Sales 2020 25.8 x
P/E ratio 2019
-485 x
P/E ratio 2020
-130 x
Employees 71
Yield 2019 *
-
Yield 2020
-
Free-Float 79.81%
More Fundamentals * Assessed data
Dynamic Chart
Helixmith Co., Ltd announced that it has received KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd. CI
Helixmith Co., Ltd announced that it expects to receive KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd. CI
Bio Solution Co.,Ltd.(KOSDAQ:A086820) dropped from S&P Global BMI Index CI
Biosolution Co.,Ltd. agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion. CI
Bio Solution Co.,Ltd. announced that it has received KRW 42 billion in funding from Eum Private Equity, IBK Capital Corporation CI
Bio Solution Co.,Ltd. announced that it has received KRW 60 billion in funding from Eum Private Equity, IBK Capital Corporation and other investors CI
Bio Solution Co.,Ltd. announced that it expects to receive KRW 80 billion in funding from Eum Private Equity, IBK Capital Corporation CI
Biosolution Co., Ltd.(KOSDAQ:A086820) added to S&P Global BMI Index CI
Biosolution Co., Ltd. has completed an IPO in the amount of KRW 43.5 billion. CI
Biosolution Co., Ltd. has filed an IPO. CI
Biosolution Co., Ltd. has withdrawn its IPO. CI
Biosolution Co., Ltd. has filed an IPO. CI
MCTTBio Co.,Ltd. has withdrawn its IPO. CI
Modern Cell & Tissue Technologies, Inc. announced that it has received KRW 4 billion in funding from Hyundai Venture Investment Corp. and Korea Investment Partners Co. Ltd. CI
Modern Cell & Tissue Technologies, Inc. announced that it expects to receive KRW 4 billion in funding from Hyundai Venture Investment Corp. and Korea Investment Partners Co. Ltd. CI
More news
1 day+0.38%
1 week+0.60%
Current month+13.40%
1 month+13.05%
3 months-4.67%
6 months+28.10%
Current year-5.26%
More quotes
1 week
17 700.00
Extreme 17700
18 640.00
1 month
15 220.00
Extreme 15220
18 660.00
Current year
14 960.00
Extreme 14960
21 850.00
1 year
9 210.00
Extreme 9210
24 050.00
3 years
9 210.00
Extreme 9210
32 950.00
5 years
9 210.00
Extreme 9210
72 000.00
10 years
9 210.00
Extreme 9210
72 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 -
Director of Finance/CFO 56 -
Chief Tech/Sci/R&D Officer 52 -
Members of the board TitleAgeSince
Chief Executive Officer 67 -
Director/Board Member 68 -
Director/Board Member 72 -
More insiders
Date Price Change Volume
24-03-28 17,600 -4.19% 33,300
24-03-27 18,370 +0.38% 25,735
24-03-26 18,300 -0.54% 29,975
24-03-25 18,400 +1.66% 25,650
24-03-22 18,100 -0.55% 17,221

End-of-day quote Korea S.E., March 26, 2024

More quotes
Bio Solution Co.,Ltd. is a Korea based company mainly engaged in the manufacturing and distribution of cell therapy products. The Company manufactures and sells cell based cosmetic raw materials and therapeutics with background in somatic and stem cell technology. The Company's major products include cosmetic raw material called stem water, which contains human stem cells has whitening and anti-wrinkling effects; as well as keratinocyte medication for severe burns and chondrocyte therapy product used to cure arthritis. The Company also researches and develops human tissue models for toxicity and efficacy testing using tissue engineering technology.
More about the company
  1. Stock
  2. Equities
  3. Stock Bio Solution Co.,Ltd. - Korea S.E.